GSK and Hansoh press on despite Pfizer’s exit
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
A fourth challenger from DualityBio and BioNTech
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
ESMO 2024 – MediLink impresses in small-cell lung cancer
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.
Novartis calls time on TIM-3 and HIF2α
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
TROP2 gets more crowded
The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.
Merck KGaA takes another shot at PARP1
But today’s deal with Jiangsu Hengrui doesn’t mean that the group is turning away from an earlier tie-up with Nerviano.
